Maria Leu, MD
Pulmonary Disease · Rock Hill, SCNPI 1760772602
Payments from drug & device makers
Across 360 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Mallinckrodt Hospital Products Inc.$609
- Boehringer Ingelheim$420
- Grifols USA, LLC$394
- Regeneron Healthcare Solutions, Inc.$360
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,99497%
- Education$1953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,781 |
| GSK | 62 | $1,119 |
| Mallinckrodt Hospital Products Inc. | 30 | $609 |
| Boehringer Ingelheim | 19 | $420 |
| Grifols USA, LLC | 21 | $394 |
| Regeneron Healthcare Solutions, Inc. | 16 | $360 |
| Sanofi | 16 | $314 |
| Mylan Specialty L.p. | 14 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $264 |
| Verona Pharma, Inc. | 12 | $260 |
| Insmed, Inc. | 14 | $235 |
| Actelion Pharmaceuticals US, Inc. | 5 | $198 |
| Inogen, Inc. | 11 | $171 |
| Merck | 7 | $154 |
| Philips North America LLC | 6 | $125 |
| United Therapeutics Corporation | 3 | $98 |
| Pfizer | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Baxter Healthcare | 2 | $48 |
| Genentech USA, Inc. | 3 | $45 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Viatris Specialty LLC | 2 | $39 |
| Covis Pharma GmbH | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Shionogi Inc | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,189 in reported general payments places this provider in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 763 | $591,100 |
| OfevNintedanib Esylate | 22 | $274,538 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 240 | $178,151 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $56,528 |
| Incruse ElliptaUmeclidinium Bromide | 145 | $52,679 |
| Spiriva RespimatTiotropium Bromide | 95 | $51,872 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $41,972 |
| Spiriva HandihalerTiotropium Bromide | 72 | $41,904 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $33,008 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $28,565 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 187 | $23,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 992 | $20,975 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $20,053 |
| Atrovent HfaIpratropium Bromide | 41 | $19,224 |
| Wixela InhubFluticasone Propion/Salmeterol | 127 | $17,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,119 | $750,2051,152 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $420 | $375,027192 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,781 | $219,828366 claims |
| MerckDulera | $154 | $8,71119 claims |
| PfizerEliquis | $72 | $8,04014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Rock Hill
- Michael DenenbergRock Hill$3.1M
- Arun AdlakhaRock Hill$335K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
- Richard BoganColumbia$4.8M
- Patrick FlumeCharleston$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.